Samuel Z. Goldhaber, MD, Professor of Medicine at Harvard Medical School, is Director of Faculty Promotions in the Division of Cardiovascular Medicine at Brigham and Women’s Hospital (BWH). He directs the BWH Thrombosis Research Group. Dr. Goldhaber serves as Principal Investigator for an array of observational and randomized trials studying venous thromboembolism, stroke prevention in atrial fibrillation (AF), and direct oral anticoagulants.

Dr. Goldhaber showed that right ventricular dilatation and hypokinesis predict an adverse prognosis in acute pulmonary embolism. He was Principal Investigator of pivotal trials leading to the FDA’s approval of systemically administered TPA and, subsequently, ultrasound-facilitated, catheter-directed thrombolysis for submassive and massive pulmonary embolism. For his work on prevention of venous thromboembolism, Dr. Goldhaber received the Certificate of Appreciation from the Surgeon General of the United States. He has also received the Distinguished Scientist Award from the American Heart Association. His clinical research interests are now evolving to include weight management and autonomic nervous system dysfunction due to COVID.

In 2006, Dr. Goldhaber founded the North American Thrombosis Forum (www.Thrombosis.org), a nonprofit organization which focuses on thrombosis education for healthcare providers, patients, and the public. Dr. Goldhaber also runs a busy ambulatory practice for general cardiology, vascular medicine, venous thromboembolism, atrial fibrillation, weight management, and autonomic dysfunction patients.